The European Medicines Agency (EMA) issued several recommendations on Wednesday 19 October in favour of vaccines against Covid-19.
The EMA is recommending the authorisation of the bivalent Covid-19 vaccine (Spikevax) developed by the pharmaceutical company Moderna, adapted not only to fight the original SARS-CoV-2 strain, but also two of its sub-variants of concern: BA.4 and BA.5. This vaccine is intended for people over 12 years of age who have already completed a first vaccination...